0001019687-16-005970.txt : 20160425 0001019687-16-005970.hdr.sgml : 20160425 20160425090248 ACCESSION NUMBER: 0001019687-16-005970 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20160422 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160425 DATE AS OF CHANGE: 20160425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SIMULATIONS PLUS INC CENTRAL INDEX KEY: 0001023459 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373] IRS NUMBER: 954595609 FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32046 FILM NUMBER: 161587981 BUSINESS ADDRESS: STREET 1: 42505 10TH STREET WEST STREET 2: * CITY: LANCASTER STATE: CA ZIP: 93534-7059 BUSINESS PHONE: 661-723-7723 MAIL ADDRESS: STREET 1: 42505 10TH STREET WEST CITY: LANCASTER STATE: CA ZIP: 93534-7059 8-K 1 simulations_8k.htm FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

April 22, 2016

(Date of the earliest event reported)

 

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

 

California   001-32046   95-4595609
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)

 

42505 10th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

 

661-723-7723

Registrant's telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

  

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

 

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

   
 

 

 

Item 7.01 Regulation FD Disclosure

 

On April 22, 2016, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing that its board of directors has declared a quarterly cash dividend of $0.05 per share of common stock, payable on May 9, 2016 to shareholders of record on May 2, 2016.

A copy of press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

The information contained in this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This Current Report on Form 8-K may contain forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained in this Current Report or with respect to the announcements described herein.

 

Item 9.01 Financial Statements and Exhibits

 

(c) Exhibits

 

99.1Press release issued on April 22, 2016.

 

 

 

 

 

 2 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

  SIMULATIONS PLUS, INC.
   
Dated: April 25, 2016 By:  /s/ John R. Kneisel
    John R. Kneisel
Chief Financial Officer

 

 

 

EX-99.1 2 simulations_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

For Further Information:

Simulations Plus, Inc.

42505 10th Street West

Lancaster, CA 93534-7059

 

CONTACT:      
Simulations Plus Investor Relations     Hayden IR
Ms. Renee Bouche     Mr. Cameron Donahue
661-723-7723     651-653-1854
renee@simulations-plus.com     cameron@haydenir.com

 

For Immediate Release:

April 22, 2016

 

Simulations Plus Announces Quarterly Cash Dividend of $0.05 Per Share

 

LANCASTER, CA, April 22, 2016 – Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its board of directors has declared its next ongoing quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Monday, May 9, 2016, to shareholders of record as of Monday, May 2, 2016.

 

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “This dividend declaration is a continuation of the Board’s plan to distribute a cash dividend of $0.05 per share per quarter. Of course, the board always has the discretion of discontinuing, increasing, or decreasing the dividend in accordance with the cash needs of the business.”

 

About Simulations Plus, Inc.

 

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions. For more information, visit our website at www.simulations-plus.com.

 

###

 

 

GRAPHIC 3 image_001.gif GRAPHIC begin 644 image_001.gif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a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end